Immunotherapy in thymic epithelial tumors: tissue predictive biomarkers for immune checkpoint inhibitors
Exploration of Targeted Anti-tumor Therapy · 21.05.2024 · 5 (3)
DOI: 10.37349/etat.2024.00229 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Exploration of Targeted Anti-tumor Therapy, online erschienen am 21.05.2024. Verfasst von Stefano Lucà und 3 weiteren Autor:innen. Beteiligte Einrichtung: Pathology Unit, Department of Mental and Physical Health and Preventive Medicine, Università degli Studi della Campania "L. Vanvitelli", 80138 Naples…. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Thymic epithelial tumors (TETs) are rare malignant neoplasms arising in the thymus gland. Nevertheless, TETs, including thymomas (TMs), thymic carcinomas (TCs), and thymic neuroendocrine neoplasms (TNENs), are the most common mediastinal malignancies overall. A multidisciplinary approach is required for the appropriate diagnostic and therapeutic management of TETs. To date, the main therapeutic strategies are largely depended on the stage of the tumor and they include surgery with or without neoadjuvant or adjuvant therapy, represented by platinum-based chemotherapy, radiotherapy or chemoradiotherapy. Immune checkpoint inhibitors (ICIs) are ongoing under evaluation in the advanced or metastatic diseases despite the challenges related to the very low tumor mutation burden (TMB) and the high incidence of immune-related adverse events in TETs. In this regard, predictive impact of tissue biomarkers expression such as programmed cell death ligand-1 (PD-L1), and other emerging biomarkers, as well as their optimal and shared interpretation are currently under evaluation in order to predict response rates to ICIs in TETs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pathology Unit, Department of Mental and Physical Health and Preventive Medicine, Università degli Studi della Campania "L. Vanvitelli", 80138 Naples, Italy.
- Department of Advanced Diagnostic-Therapeutic Technologies and Health Services Section of Anatomic Pathology, A. Cardarelli Hospital, 80131 Naples, Italy.
ORCID-Profile: Stefano Lucà, Renato Franco
Zitieren
APA
Lucà, S., Accardo, M., Campione, S., & Franco, R. (2024). Immunotherapy in thymic epithelial tumors: tissue predictive biomarkers for immune checkpoint inhibitors. Exploration of Targeted Anti-tumor Therapy, 5(3). https://doi.org/10.37349/etat.2024.00229
Vancouver
Lucà S, Accardo M, Campione S, Franco R. Immunotherapy in thymic epithelial tumors: tissue predictive biomarkers for immune checkpoint inhibitors. Exploration of Targeted Anti-tumor Therapy. 2024;5(3). doi:10.37349/etat.2024.00229
BibTeX
@article{Luc2024,
author = {Lucà, Stefano and Accardo, Marina and Campione, Severo and Franco, Renato},
title = {Immunotherapy in thymic epithelial tumors: tissue predictive biomarkers for immune checkpoint inhibitors},
journal = {Exploration of Targeted Anti-tumor Therapy},
year = {2024},
volume = {5},
number = {3},
doi = {10.37349/etat.2024.00229}
}
EUVIMED